News

May 06, 2011

Credit

PR – Marketing Dept. 

Conference and Exhibition on Drug On 06 May 2011

On 06 May 2011, STADA-VN has participated in the Conference and Exhibition on Drug held by Ho Chi Minh City Health Department together with more than 40 pharmaceutical manufacturers.

image017

In the exhibition, STADA-VN has introduced to the delegates about 90 items in product list. Most of products of STADA-VN have been highly appreciated

About STELLA

STELLAPHARM is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, anti-viral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.

The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.

Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An Town, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: info@stellapharm.com | W: www.stellapharm.com

You May like

Back
25 Sep 2026

STELLAPHARM MỞ RỘNG HỢP TÁC VỚI MPP: KÝ THỎA THUẬN CẤP PHÉP SẢN XUẤT THUỐC KHÁNG VIRUS ĐIỀU TRỊ CÚM BALOXAVIR TỪ ROCHE TẠI 129 QUỐC GIA CÓ THU NHẬP THẤP VÀ TRUNG BÌNH

Thành phố Hồ Chí Minh và Geneva, ngày 10 tháng 9 năm 2026 – Stellapharm và Medicines Patent Pool (MPP) ký Thỏa thuận cấp phép (Sublicence Agreement) về việc phát triển, sản xuất và cung ứng thuốc generic chứa hoạt chất baloxavir marboxil do Roche nắm sở hữu bản quyền. Đây là thuốc kháng virus

25 Sep 2026

STELLAPHARM BROADENS COLLABORATION WITH MPP: SIGNS SUBLICENCE AGREEMENT TO PRODUCE GENERIC VERSION OF ROCHE’S ANTIVIRAL TREATMENT FOR INFLUENZA BALOXAVIR IN 129 LOW- AND MIDDLE-INCOME COUNTRIES

Ho Chi Minh City and Geneva, 10 September 2026 – Stellapharm and Medicines Patent Pool (MPP) signed a sublicence agreement to develop, manufacture and supply a generic version of Roche’s baloxavir marboxil, a single-dose antiviral treatment recommended by the World Health Organization (WHO) for influenza. The agreement will allow Stellapharm to manufacture and supply baloxavir